Running in place
March 30, 2009 by Brian Johnson
Cambridge's InVivo Therapeutics is charging toward a cure for paralysis. Will investors come along for the ride?
CORRECTION
Inc. magazine ran the following correction Dec. 1:
Similar entries
- Invivo Therapeutics resumes second primate study
- Invivo Therapeutics CEO Reynolds wins hefty pay raise for 2011
- UPDATE: InVivo Therapeutics seeks investigational device exemption from the FDA
- InVivo Therapeutics asks FDA for permission to run human trial
- InVivo CEO hopes for FDA response by early 2012
Printer-friendly versionPermalink
FDA Database Search
Features
RECENT BLOG POSTS
- Racing to nowhere
- The politics of measuring outcomes
- Democrats set sights on medical device safety regulation
- Doctors helping doctors (and their patients) via social media
- Massachusetts miracle: Romney's health care reform plan works
- Facebook IPO: Will it hurt medical device investment?
- Revolutionizing the bone screw industry- Bioceramics
- Some downsides of social media for doctors
- Mexico expands equivalency to devices registered in Japan
- Online device and drug training benefits hospitals and medical technology companies
